font size:
杏耀平台代理注册
online message
contact information
one of telephone, mobile phone number, e-mail is required
contact
tel
mobile phone
email
qq
wechat account
message
other additions
verification code

ping an-杏耀平台代理注册

views：

sumitomo became the strategic shareholder with shareholding of 29% held in c&o. c&o board of directors has been restructured and sumitomo corporation will appoint three directors to the c&o board.

return list previous：c&o obtained manufacturing license for edaravone next：major scientific and technological projects for “major new drug initiation”
about us
about us development history company honor
business scope
market sales technology development manufacture center
products
antibiotics digestive system medication cardiovascular and cerebrovascular medication bone and muscle medication dermatological medication nervous system medication respiratory system medication others
news release
company news notice
contact us
  • official wechat account official wechat account
  • mobile pagemobile page
  • service tel0755-2552 7000
  • business tel0755-2552 7386
linkssite mapprivacy policy
杏耀平台代理注册 copyright @ 2022 c&o pharmaceutical technology (holdings) limited. all rights reserved.
网站地图